189 related articles for article (PubMed ID: 31874799)
21. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.
Tavori H; Fan D; Giunzioni I; Zhu L; Linton MF; Fogo AB; Fazio S
J Lipid Res; 2014 Oct; 55(10):2073-81. PubMed ID: 25183802
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
23. Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.
Ishigaki Y; Oikawa S; Suzuki T; Usui S; Magoori K; Kim DH; Suzuki H; Sasaki J; Sasano H; Okazaki M; Toyota T; Saito T; Yamamoto TT
J Biol Chem; 2000 Oct; 275(40):31269-73. PubMed ID: 10903326
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.
Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T
Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027
[TBL] [Abstract][Full Text] [Related]
25. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy.
Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH
Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773
[TBL] [Abstract][Full Text] [Related]
26. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature.
Kawanishi K; Sawada A; Ochi A; Moriyama T; Mitobe M; Mochizuki T; Honda K; Oda H; Nishikawa T; Nitta K
Case Rep Nephrol Urol; 2013 Jul; 3(2):128-35. PubMed ID: 24570682
[TBL] [Abstract][Full Text] [Related]
27. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
[TBL] [Abstract][Full Text] [Related]
28. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.
Mitani A; Ishigami M; Watase K; Minakata T; Yamamura T
J Atheroscler Thromb; 2011; 18(6):531-5. PubMed ID: 21325775
[TBL] [Abstract][Full Text] [Related]
29. Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
Matsunaga A; Saito T
Clin Exp Nephrol; 2014 Apr; 18(2):220-4. PubMed ID: 24570178
[TBL] [Abstract][Full Text] [Related]
30. The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.
Wu H; Yang Y; Hu Z
J Atheroscler Thromb; 2018 Aug; 25(8):733-740. PubMed ID: 29398675
[TBL] [Abstract][Full Text] [Related]
31. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.
Ito K; Nakashima H; Watanabe M; Ishimura A; Miyahara Y; Abe Y; Yasuno T; Ifuku M; Sasatomi Y; Saito T
Nephrol Dial Transplant; 2012 Oct; 27(10):3899-907. PubMed ID: 22863838
[TBL] [Abstract][Full Text] [Related]
32. Significance of a novel apolipoprotein E variant, ApoE Osaka/Kurashiki, in lipoprotein glomerulopathy.
Saito T; Matsunaga A
J Atheroscler Thromb; 2011; 18(6):542-3. PubMed ID: 21670560
[No Abstract] [Full Text] [Related]
33. Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.
Yang M; Weng Q; Pan X; Hussain HMJ; Yu S; Xu J; Yu X; Liu Y; Jin Y; Zhang C; Li X; Ren H; Chen N; Xie J
Mol Genet Genomic Med; 2020 Aug; 8(8):e1281. PubMed ID: 32441489
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.
Li Y; Chen J; Zou Y; Wang W; Li G
Medicine (Baltimore); 2022 Feb; 101(5):e28718. PubMed ID: 35119017
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T
BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490
[TBL] [Abstract][Full Text] [Related]
36. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report.
Xie W; Xie Y; Lin Z; Xu X; Zhang Y
Diagn Pathol; 2019 May; 14(1):41. PubMed ID: 31092271
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Li LS
J Nephrol; 2008; 21(1):110-7. PubMed ID: 18264944
[TBL] [Abstract][Full Text] [Related]
38. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
[TBL] [Abstract][Full Text] [Related]
39. A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.
Wang R; Zhao C; Chen W; Liu Z; Xie F
J Med Case Rep; 2022 Feb; 16(1):78. PubMed ID: 35193676
[TBL] [Abstract][Full Text] [Related]
40. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China.
Han J; Pan Y; Chen Y; Li X; Xing G; Shi J; Hou P; Zhang H; Wang H
Nephron Clin Pract; 2010; 114(4):c260-7. PubMed ID: 20090368
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
